SpyGlass Pharma, Inc. (SGP) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$24.58

From 52W high−17.12%

Volume69778.00

Market cap$822.82M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$24.58

From 52W high

−17.12%

Volume

69778.00

Market cap

$822.82M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.1x

P/E (TTM)

—

RSI (14)

47.1

MomentumView details →

1D Return

+2.50%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−10.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−24.12%

ROA (TTM)

−23.03%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+2.50%

YTD Return

—

1Y Return

—

RSI (14)

47.1

vs 50D SMA

−5.49%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

25.06x

Quick Ratio

25.06x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.59

EPS Surprise

−14.69%

Beats (12Q)

0/12

Next Q EPS Est

−$0.65

Avg Surprise (4Q)

−315.99%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−56.05M

Op. CF (TTM)

−46.56M

Next earningsNov 5, 2026 →

Latest newsMore news →

SpyGlass Pharma announced positive four-year first-in-human trial results for its BIM-IOL System, including a 37% reduction in mean intraocular pressure across dose groups, 86% of patients remaining off topical IOP-lowering drops, and 90% maintaining at least 20/25 best-corrected distance visual acuity, with no product-related adverse events reported.18h ago

SpyGlass Pharma acquired all outstanding shares of Advanced Vision Science, Inc. from Santen Pharmaceutical for approximately $13 million in cash.19d ago

Similar companies

Alumis Inc. Common StockALMS MoonLake ImmunotherapeuticsMLTX Kura Oncology, Inc.KURA Corvus Pharmaceuticals, Inc.CRVS Arbutus Biopharma CorporationABUS Aktis Oncology, Inc.AKTS Find similar companies →

Latest newsMore news →

SpyGlass Pharma announced positive four-year first-in-human trial results for its BIM-IOL System, including a 37% reduction in mean intraocular pressure across dose groups, 86% of patients remaining off topical IOP-lowering drops, and 90% maintaining at least 20/25 best-corrected distance visual acuity, with no product-related adverse events reported.18h ago SpyGlass Pharma acquired all outstanding shares of Advanced Vision Science, Inc. from Santen Pharmaceutical for approximately $13 million in cash.19d ago